Why Insulet Stock Rocked the Market Today
Medical device maker 's (NASDAQ: PODD) stock was the cure for the investor blues on Wednesday. Following news of a large insider buy, the shares subsequently shot more than 6% higher on the day. That was well higher than the sub-0.4% increase of the S 500 index.
The inside buyer of Insulet stock was none other than its CEO, James Hollingshead. In a regulatory filing, the specialty healthcare company divulged that Hollingshead had purchased 5,550 shares of its common stock on Monday.
While that doesn't look at first blush to be a big-time purchase, Insulet stock currently has a triple-digit price tag. As a result, that buy-in cost the company's leader just over $1 million.
Source Fool.com
Insulet Corp. Aktie
179,65 €
0,31 %
Die Insulet Corp. Aktie genießt klare Unterstützung: Mehrere Buy-Einschätzungen, keine Sell-Einschätzungen.
Bei einem Kursziel von 216 € für Insulet Corp. deutet sich eine Steigerung von über 20% vom aktuellen Kurs von 179.65 € an.
